Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
A Chari, J Martinez-Lopez, MV Mateos… - Blood, The Journal …, 2019 - ashpublications.org
Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
A Chari, J Martinez-Lopez, MV Mateos, J Bladé… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
[HTML][HTML] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
A Chari, J Martinez-Lopez, MV Mateos, J Bladé… - Blood, 2019 - Elsevier
Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
[HTML][HTML] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
A Chari, J Martinez-Lopez, MV Mateos, J Bladé… - Blood, 2019 - ncbi.nlm.nih.gov
Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
A Chari, J Martinez-Lopez, MV Mateos, J Bladé… - Blood, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Patients with relapsed or refractory multiple
myeloma (RRMM) have limited treatment options and poor survival outcomes. The …
myeloma (RRMM) have limited treatment options and poor survival outcomes. The …
[引用][C] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
A Chari, J Martinez-Lopez, MV Mateos, J Bladé… - …, 2019 - produccioncientifica.ucm.es
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
A Chari, J Martinez-Lopez, MV Mateos, J Bladé… - Blood, 2019 - europepmc.org
Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
[PDF][PDF] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
P Rodriguez-Otero, L Pineiro, A Jakubowiak, C de Boer… - blood, 2019 - academia.edu
Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
A Chari, J Martinez-Lopez, MV Mateos, J Bladé… - Blood, 2019 - europepmc.org
Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …